FDA Panel Narrowly Backs Multi-Cancer Blood Test Despite Doubts It Works

Key TakeawaysA divided U.S. Food and Drug Administration advisory panel narrowly backed Galleri, a blood test that screens for dozens of cancersA large trial in England found the test didn't reduce late-stage cancer diagnoses, raising questions about how well it worksExperts warn a negative result doesn't rule out cancer and shouldn't replace proven screenings like colonoscopy.THURSDAY, Sept. 24, 2026 (HealthDay News) — A blood test that aims to catch more than 50 types of cancer before symptoms appear narrowly won the backing of U.S. Food and Drug Administration (FDA) advisers Wednesday, even as several doubted it works.The test, called Galleri, looks for bits of DNA in the blood that may signal cancer. Its maker, Grail, says it can spot cancers of the stomach, bladder, colon, skin and breast, among others, reports The Washington Post.Galleri has been sold in the United States since 2021 without FDA approval and costs nearly $1,000. Grail applied for approval in February and says the test, meant for adults 50 and older, shouldn't replace standard screenings.The FDA's 10-member advisory committee declared in a 6-4 vote that the test is effective.On whether its benefits outweigh its risks, members voted 7-2, with one abstention. All agreed it's safe.Some members said finding cancers that have no screening option today made the test worth backing, but others voted yes with open reservations, The Post reported."If we can find more Stage 1 or more early-stage cancers in a population that we can't screen for currently, then that will end up having benefit," said committee member Dr. Victor van Berkel, division chief of thoracic surgery at the University of Louisville in Kentucky. "But I don't know that that's been proven yet. So perhaps my 'yes' is a hopeful [vote] rather than an accurate one."Much of that doubt traces to a trial with England’s National Health Service (NHS) involving more than 140,000 people. The trial's main goal was to lower the rate of stage 3 and 4 diagnoses across 12 cancers. It didn't, Grail announced earlier this year.Other research paints a more hopeful picture. In a Grail-funded study published Sept. 22 in Nature Medicine, researchers tested more than 32,000 adults 50 and older with no signs of cancer.About 6 in 10 people who got a positive result turned out to have cancer. More than half of the new cancers the test caught were early stage, and most were types that have no routine screening.Dr. William Dahut, chief scientific officer of the American Cancer Society, told the committee that testing for many cancers at once is more efficient than building a separate test for each one."No screening test is perfect," he said. "... but if we sit in a room for the next 20 years trying to find the perfect test, we have a large possibility we're going to lead to more cancer deaths."Dr. Emil Lou, an oncologist at the University of Minnesota, warned that the test can still raise false alarms, which may lead to stress and needless procedures. It can also miss cancers, giving people false comfort, he said.Dr. Scott Ramsey, a researcher at Fred Hutchinson Cancer Center in Seattle, said the NHS results call the test's early-detection value into question."There's no proof that this is going to reduce your risk of dying from cancer," Ramsey said. "If you have a negative test, you should not feel reassured [and] continue with [cancer screenings] that have been proven."Grail's proposed label would say a negative result doesn't rule out cancer, a positive one needs follow-up testing and isn't a diagnosis, and the test can miss cancers or give false results.The FDA often follows its advisers but makes its own call. Grail expects a final decision on FDA approval in the coming months.More informationVisit the American Cancer Society for more information about recommended cancer screenings.SOURCES: The Washington Post, Sept. 24, 2026; Nature Medicine, Sept. 22, 2026 .What This Means For YouResearch into new ways to detect cancer early is ongoing, but these methods haven’t replaced standard screenings yet. Talk to your doctor about which cancer screenings you should schedule..Sign up for our weekly HealthDay newsletter

FDA Panel Narrowly Backs Multi-Cancer Blood Test Despite Doubts It Works

Related Stories

Blood Test Could Spot Deadly Pancreatic Cancer Sooner

Less Overdiagnosis In Breast Cancer Screening Than Thought, Study Finds

FDA Approves New Pill For Advanced Breast Cancer Guided By Blood Test

FDA Authorizes First Wearable To Track Both Ketones And Blood Sugar